Gyre Therapeutics, Inc. (GYRE)
(Delayed Data from NSDQ)
$9.36 USD
-0.56 (-5.65%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $9.20 -0.16 (-1.71%) 6:00 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Income Statements
Fiscal Year end for Gyre Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 113 | 1 | 7 | 21 | 0 |
Cost Of Goods | 5 | 1 | 7 | 9 | 0 |
Gross Profit | 109 | 0 | 0 | 12 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 176 | 9 | 88 | 69 | 57 |
Income After Depreciation & Amortization | -67 | -9 | -88 | -57 | -57 |
Non-Operating Income | -10 | 1 | 0 | 1 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -77 | -8 | -88 | -56 | -55 |
Income Taxes | 9 | 0 | 0 | 0 | 0 |
Minority Interest | 7 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -85 | -8 | -88 | -56 | -55 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -93 | -8 | -88 | -56 | -55 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -66 | -8 | -88 | -57 | -57 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -67 | -9 | -88 | -57 | -57 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 65.83 | 2.10 | 2.04 | 1.28 | 0.80 |
Diluted EPS Before Non-Recurring Items | 0.27 | -31.18 | -43.03 | -43.93 | -68.97 |
Diluted Net EPS (GAAP) | -1.41 | -3.90 | -43.03 | -43.93 | -68.97 |
Fiscal Year end for Gyre Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 27.17 | 113.45 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.98 | 4.64 | 0.00 | 0.00 | 0.00 |
Gross Profit | 26.19 | 108.81 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 18.12 | 172.05 | 1.63 | 2.55 | -0.18 |
Income After SG&A, R&D, and Dept/Amort Expenses | 8.07 | -63.24 | -1.63 | -2.55 | 0.18 |
Non-Operating Income | 4.41 | 0.83 | 0.05 | 0.07 | 0.10 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 12.48 | -73.19 | -1.58 | -2.47 | 0.27 |
Income Taxes | 2.55 | 8.50 | 0.00 | 0.00 | 0.01 |
Minority Interest | 2.40 | 7.45 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 9.93 | -81.69 | -1.58 | -2.47 | 0.26 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 7.53 | -89.15 | -1.58 | -2.47 | 0.26 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 102.59 | NA | 2.53 | 2.52 | 2.53 |
Diluted EPS Before Non-Recurring Items | 0.04 | NA | -0.60 | -1.05 | -1.65 |
Diluted Net EPS (GAAP) | 0.03 | 0.09 | -0.60 | -1.05 | 0.15 |